- Refine the classification of different solid tumors types including colon, renal, lung cancers, hepatocellular carcinoma and rare endocrine tumors by associating genomics and immunology research fields. In RCC this classification constitutes the basis for a biomarker driven trial with nivolumab, ipilimumab and VEGFR TKi (BIONIKK. NCT02960906).
- Decipher prognostically relevant subgroups of leukemia and lymphoma patients by wide somatic alterations screening and apply this knowledge to detect minimal residual disease by deep sequencing strategies and single cell digital droplet PCR.
- Validate circulating tumor DNA detection as a prognostic and predictive marker of chemotherapy efficacy as well as a surrogate marker of solid biopsies in lung, colon and pancreatic cancers.
- Identify some innovative immunotherapeutic strategies from the comprehensive analysis of tumor microenvironment such as combining anti-angiogenic molecules with immunomodulators, reinforcing tumor immunosurveillance via caloric restriction to induce autophagy or the harnessing of resident memory T cells.
- Validate the immunoscore™ at the international level through a consortium associating 22 centers lead by one CARPEM team
- Develop a common data warehouse with innovative bioinformatics tools which has acted as an accelerator to implement clinical bioinformatics pipelines in the hospital and translation to patient care.
- To improve the collection and the number of samples that could be used for research, CARPEM teams established a new informed consent form for all cancer patients (OncoHEGP – OncoCCH). A video was made to explain the importance of signing a consent and allowing patients to become actors in research.
- Realization of 20 educational videos around personalized medicine by CARPEM members.
- Creation of two patient committees on improving patient information and ethics during data collection. The two committees merged into a single board called “Advisory translational ethic board” (ATEB).
